NGAL

The assays measure biomarkers — NGAL and KIM-1 — that the company said will help drug developers gauge the right dose for drugs in Phase I trials, validate proof-of-concept in Phase II, and confirm efficacy and safety in Phase III studies by helping avoid kidney damage in participants.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.